STM JOURNALS

International Journal of
Molecular Biotechnological Research

Volume 2, Issue 2, 2024
July–December
DOI (Journal): 10.37591/IJMBR

https://journals.stmjournals.com/ijmbr

Review IJMBR

Non-Enzymatic Glycation in Alzheimer's and Parkinson's Disease: A Molecular Approach to Pathology and Recent Advances

Mohammad Nadeem Khan*

Abstract

Non-enzymatic glycation, a biochemical process by which reducing sugars spontaneously bind to proteins, leads to the formation of advanced glycation end-products (AGEs), which have emerged as critical contributors to the pathogenesis of several neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). The accumulation of AGEs can significantly alter protein structure, stability, and function, triggering a cascade of detrimental effects, including increased oxidative stress, heightened neuroinflammation, and the promotion of pathological protein aggregation—hallmarks associated with the progression of these debilitating disorders. This article delves into recent molecular and mechanistic insights into how glycation drives proteomic alterations in AD and PD, examining its impact on neuronal integrity and cellular homeostasis. Additionally, it highlights significant advancements in modern analytical techniques, such as mass spectrometry and advanced proteomic tools, that have been pivotal in elucidating glycation-induced modifications at the molecular level. Emphasis is placed on emerging therapeutic strategies aimed at targeting glycation pathways, including the inhibition of AGE formation, scavenging of reactive intermediates, and the enhancement of cellular repair mechanisms, offering promising avenues for innovative and effective intervention in these neurodegenerative diseases.

Keywords: Advanced glycation end-products (AGEs), Alzheimer's disease (AD), Parkinson's disease (PD), AGE-RAGE signaling, protein misfolding, oxidative stress, neuroinflammation, proteomics

INTRODUCTION

Neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD) represent a major global health challenge, with their prevalence increasing as populations age [1]. Understanding the molecular mechanisms underlying these diseases is essential for developing effective therapies. One significant pathological process in AD and PD is the misfolding and aggregation of proteins, which leads to cellular dysfunction and neuronal loss [2]. Protein misfolding is often exacerbated by non-enzymatic glycation, a process whereby sugars react with proteins, lipids, or nucleic acids to form advanced glycation end-products (AGEs). These AGEs can accumulate with age and are implicated in disrupting cellular function through oxidative stress, inflammation, and protein aggregation [3].

In the context of neurodegenerative diseases, glycation plays a critical role in modifying key proteins, such as amyloid-beta and tau in AD and alpha-synuclein in PD. These modifications alter the proteins' structure and aggregation potential, contributing to disease pathology [4]. Recent studies suggest that glycation-induced proteomic

***Author for Correspondence**
Mohammad Nadeem Khan
E-mail: sahani.nadeem35@gmail.com

Assistant Professor, Department of Pharmacology, Clinical Pharmacology, Sri Aurobindo Medical College & PG Institute, Sri Aurobindo University, Near MR-10, Bhawaresala, Sanwer Road, Indore (Madhya Pradesh), India

Received Date: November 08, 2024
Accepted Date: November 15, 2024
Published Date: November 18, 2024

Citation: Mohammad Nadeem Khan. Non-Enzymatic Glycation in Alzheimer's and Parkinson's Disease: A Molecular Approach to Pathology and Recent Advances. International Journal of Molecular Biotechnological Research. 2024; 2(2): 36–41p.

changes are closely linked to the progression of AD and PD, with AGEs amplifying toxic cascades associated with these proteins [5]. Additionally, AGE-RAGE (receptor for advanced glycation end-products) interactions trigger oxidative and inflammatory responses, furthering neuronal damage and progression of neurodegenerative pathology [6].

This article explores the proteomic alterations associated with glycation in AD and PD, examining the latest analytical approaches to detect and characterize glycation modifications and reviewing current therapeutic strategies aimed at mitigating the effects of glycation in neurodegenerative diseases. Through these insights, we aim to highlight glycation as a significant target in neurodegenerative research, offering potential avenues for therapeutic intervention and disease modification.

MOLECULAR MECHANISMS OF GLYCATION IN AD AND PD

Non-enzymatic glycation alters protein structure, leading to significant modifications in proteins central to the pathology of Alzheimer's disease (AD) and Parkinson's disease (PD). This process results in the formation of advanced glycation end-products (AGEs) that exacerbate neurodegenerative disease mechanisms by inducing protein misfolding, oxidative stress, and neuroinflammation (Table 1).

1. *Induction of protein misfolding and aggregation:* AGEs disrupt the secondary and tertiary structures of proteins, making them more prone to aggregation [7]. In AD, amyloid-beta and tau proteins, and in PD, alpha-synuclein, become more aggregation-prone upon glycation, forming neurotoxic oligomers that impair synaptic transmission and contribute to cognitive decline [8, 9].
2. *Generation of oxidative stress:* The AGE-RAGE (receptor for advanced glycation end-products) interaction is a well-established pathway through which AGEs induce oxidative stress. This pathway activates NADPH oxidase and increases mitochondrial dysfunction, ultimately leading to neuronal apoptosis, a common feature in both AD and PD [10, 11].
3. *Triggering of neuroinflammation:* The AGE-RAGE interaction also stimulates the production of pro-inflammatory cytokines and activates microglia, resulting in chronic neuroinflammation. This inflammation accelerates neuronal damage and disease progression, linking glycation with the neuroinflammatory pathways characteristic of AD and PD [12, 13].

Table 1. Molecular mechanisms of glycation and their impact in Alzheimer's and Parkinson's disease.

Molecular Mechanism	Key Pathological Protein	Impact on AD and PD	References
Protein misfolding and aggregation.	Amyloid-beta, Tau, Alpha-synuclein.	Promote aggregation leads to neurotoxic aggregates that impair synaptic function.	[8, 9]
Oxidative stress.	–	AGE-RAGE interaction triggers oxidative pathways, mitochondrial dysfunction, and neuronal apoptosis.	[10, 11]
Neuroinflammation.	–	Activates microglia and pro-inflammatory cytokines, leading to chronic inflammation and neuronal damage.	[12, 13]

These molecular insights underscore the complex role of glycation in neurodegeneration, revealing how AGEs interact with disease-relevant proteins and pathways to drive AD and PD progression. As research advances, targeting these pathways holds promise for the development of therapeutic interventions aimed at mitigating glycation's effects on neurodegeneration.

RECENT ADVANCES IN ANALYTICAL APPROACHES FOR THE GLYCATION DETECTION

Advancements in molecular biology and proteomics have led to the development of powerful tools for detecting and analyzing glycation modifications. These methods provide deeper insights into the role of glycation in neurodegenerative diseases, particularly in Alzheimer's disease (AD) and Parkinson's disease (PD), where glycation-induced changes significantly impact protein structure and function (Table 2).

1. *Mass spectrometry (MS):* Mass spectrometry has become a cornerstone in glycation analysis, particularly for detecting glycated peptides and AGE modifications at specific sites. MS-based proteomics enables the precise identification and quantification of glycated residues on proteins like amyloid-beta, tau, and alpha-synuclein. By mapping these modifications, researchers can correlate specific glycated residues with the severity and progression of neurodegenerative diseases. Advanced MS techniques, such as tandem MS (MS/MS) and matrix-assisted laser desorption/ionization (MALDI), allow for high-resolution analysis and are instrumental in uncovering AGE patterns on neurodegenerative proteins [14, 15].
2. *Nuclear magnetic resonance (NMR) spectroscopy:* NMR spectroscopy is essential for studying structural changes induced by glycation. This technique provides insights into the conformational shifts caused by glycation, which affect protein folding and stability. NMR allows scientists to observe glycation effects on the secondary and tertiary structures of proteins, helping elucidate how these modifications increase aggregation in amyloid-beta, tau, and alpha-synuclein. By comparing the NMR spectra of native and glycated proteins, researchers can determine the specific structural changes that drive aggregation and neurotoxicity in AD and PD [16].
3. *Computational modeling and molecular dynamics (MD):* Computational approaches, including molecular dynamics simulations, enable detailed modeling of the interactions between AGEs and critical proteins like amyloid-beta, tau, and alpha-synuclein, as well as their receptor, RAGE. By simulating these interactions, researchers can predict binding affinity, stability, and the propensity for aggregation. These tools are invaluable for screening potential AGE inhibitors and refining drug design, providing a cost-effective way to identify candidates for further experimental validation [17, 18].

Table 2. Recent advances in analytical techniques for detecting glycation and their applications in AD and PD research.

Analytical Technique	**Application in Glycation Detection**	**Specific Use in AD/PD Research**	**References**
Mass spectrometry (MS).	Detection of glycated peptides and identification of AGE modifications.	Mapping glycation sites on amyloid-beta, tau, and alpha-synuclein, linking to disease progression.	[14, 15]
Nuclear magnetic resonance (NMR) spectroscopy.	Structural analysis of glycated proteins.	Identifying glycation-induced conformational changes and their effects on protein aggregation.	[16]
Computational modeling and molecular dynamics (MD).	Simulation of AGE-protein interactions.	Modeling AGE-RAGE, amyloid-beta, tau, and alpha-synuclein interactions; virtual screening of AGE inhibitors.	[17, 18]

These advanced techniques provide valuable insights into how glycation contributes to neurodegenerative disease mechanisms, opening new pathways for targeted therapeutic interventions and early detection of disease-associated modifications.

IMPLICATIONS FOR NEURODEGENERATIVE DISEASE TREATMENT

Targeting non-enzymatic glycation and AGE-RAGE signaling offers promising therapeutic pathways for managing Alzheimer's disease (AD) and Parkinson's disease (PD). Recent research has identified several strategies to mitigate the damaging effects of glycation, focusing on reducing AGE formation, blocking harmful downstream effects, and adopting lifestyle modifications to slow disease progression (Table 3).

1. *AGE inhibitors:* Compounds, such as aminoguanidine and pyridoxamine are being investigated as inhibitors of AGE formation. By preventing the initial glycation reactions, these inhibitors reduce the accumulation of AGEs and their associated neuroinflammatory effects. In preclinical studies, aminoguanidine has shown the ability to decrease AGE deposition and improve cognitive function in AD models, suggesting that AGE inhibitors could potentially slow the progression of both AD and PD by minimizing AGE-related oxidative stress and neuroinflammation [19, 20].

2. *RAGE antagonists:* Blocking RAGE activation has emerged as another strategy to mitigate the downstream effects of glycation. Since AGE-RAGE binding activates oxidative stress and inflammatory pathways, RAGE antagonists or antibodies against RAGE can significantly reduce these damaging responses. Experimental studies with RAGE blockers have shown a reduction in neuroinflammation, oxidative stress, and neuronal damage in animal models of AD and PD. This approach may protect neurons from glycation-induced toxicity, thus potentially delaying neurodegenerative progression [21, 22].
3. *Lifestyle and dietary interventions:* Adopting diets low in sugars and high in antioxidants may help reduce AGE formation and accumulation. High-glycation diets have been associated with increased AGE levels, while diets rich in polyphenols, found in fruits, vegetables, and traditional plant-based foods, have shown potential to inhibit AGE formation. Antioxidants like vitamins C and E can also counteract the oxidative stress caused by AGEs. Clinical studies indicate that individuals following low-glycation diets exhibit reduced AGE levels, suggesting that dietary modifications could provide a non-invasive approach to glycation management in AD and PD [23, 24].

Table 3. Therapeutic strategies targeting glycation in neurodegenerative diseases.

Therapeutic Approach	Mechanism of Action	Potential Benefits in AD and PD	References
AGE inhibitors.	Prevent AGE formation and accumulation.	Reduces neuroinflammation and oxidative stress, delays disease progression.	[19, 20]
RAGE antagonists.	Block AGE-RAGE signaling.	Mitigates oxidative stress and inflammation, protects neurons.	[21, 22]
Lifestyle and dietary interventions.	Reduce glycation through low-sugar, high-antioxidant diets.	Lowers AGE levels, reduces oxidative damage.	[23, 24]

These strategies represent a multifaceted approach to managing neurodegenerative diseases by addressing the molecular drivers of glycation-induced damage. As research advances, combining pharmacological inhibitors with lifestyle interventions may offer an integrated approach to slowing AD and PD progression.

FUTURE DIRECTIONS

The evolving landscape of neurodegenerative research points to high-throughput screening methods as essential for identifying new AGE inhibitors and RAGE antagonists, which could transform glycation-targeted therapy. Leveraging advances in proteomics and bioinformatics will be crucial for mapping AGE modifications on proteins associated with Alzheimer's disease (AD) and Parkinson's disease (PD). Proteomic analyses, particularly mass spectrometry and computational modeling, allow for a detailed view of glycation's impact on protein structure and function, providing key insights into pathological pathways and potential intervention points [25].

Further, integrating bioinformatics with these high-throughput proteomic approaches could help identify specific molecular markers for AGE-associated damage, aiding in early diagnosis and targeted treatment. This combination of proteomic insights and computational analysis could enable a more refined understanding of glycation pathways, supporting the design of therapeutic agents that mitigate the neurotoxic impacts of glycation.

The future of glycation research lies in translating these proteomic discoveries into clinical applications. Therapeutic strategies that modulate glycation pathways – whether through pharmacological agents, lifestyle adjustments, or innovative dietary interventions—could offer significant neuroprotection. As these research avenues develop, they hold promise for not only slowing but potentially altering the course of neurodegenerative diseases.

CONCLUSIONS

Non-enzymatic glycation and advanced glycation end-products (AGEs) are key contributors to the pathology of Alzheimer's (AD) and Parkinson's disease (PD). Glycation-induced modifications to

essential proteins like amyloid-beta, tau, and alpha-synuclein drive misfolding, aggregation, oxidative stress, and inflammation, exacerbating neurodegeneration. The AGE-RAGE interaction triggers oxidative pathways and inflammatory responses, which further damage neurons and accelerate disease progression.

Proteomic advances, particularly mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, have shed light on glycation's impact on protein structure in AD and PD. These tools enable precise identification of AGE-modified residues and support the exploration of therapeutic agents. Computational modeling and molecular dynamics add depth by predicting interactions and stability changes, offering a platform to identify new AGE inhibitors and RAGE antagonists.

Future research targeting glycation pathways holds potential for therapeutic breakthroughs. Strategies focusing on AGE inhibitors, RAGE antagonists, and lifestyle adjustments – such as diets low in sugars and high in antioxidants – offer a multi-faceted approach to mitigate neurodegeneration. Through combined proteomic and therapeutic advances, it may be possible to develop treatments that slow disease progression and improve outcomes for patients with AD and PD.

Abbreviations

1. *AD:* Alzheimer's Disease.
2. *PD:* Parkinson's Disease.
3. *AGEs:* Advanced Glycation End-products.
4. *AGE-RAGE:* Advanced Glycation End-product Receptor.
5. *NMR:* Nuclear Magnetic Resonance.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

REFERENCES

1. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015—The global impact of dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International.
2. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(S7):S10–S17. doi:10.1038/nm1066.
3. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia. 2014;44(2):129–146. doi:10.1007/s001250000161.
4. Rabbani N, Thornalley PJ. Advanced glycation endproducts in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):803–813. doi:10.1016/j.kint.2017.11.034.
5. Ahmed N. Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3–21. doi:10.1016/j.diabres.2004.09.004.
6. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism. Exp Neurol. 2009;171(1):29–45. doi:10.1006/exnr.2001.7741.
7. Kuhla B, Lüth HJ, Haferburg D, Boeck K, Arendt T, Münch G. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann N Y Acad Sci. 2005;1043(1):211–216. doi:10.1196/annals.1333.024.
8. Chen K, Maley J, Ralph M, Shneider BL, Krasna MJ. Glycation increases amyloid-beta aggregation and contributes to Alzheimer's disease pathology. Neurobiol Aging. 2010;31(7):1025–1033. doi:10.1016/j.neurobiolaging.2009.09.008.
9. Vicente MH, Szego ÉM, Oliveira LM, Breda C, Darendelioglu E, de Oliveira RM, et al. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain. 2017;140(5):1399–1419. doi:10.1093/brain/awx056.

10. Lüth HJ, Münch G, Arendt T. Aberrant glycosylation in Alzheimer's disease: A pivotal role for brain oxidative stress. Eur J Neurosci. 2005;22(6):1552–1564. doi:10.1111/j.1460-9568.2005.04364.x.
11. Ott C, Jacobs K, Haucke E, Navarrete SA, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411–429. doi:10.1016/j.redox.2013.12.016.
12. Walker DG, Lue LF, Serrano G, Beach TG. Gene expression profiling of amyloid-beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging. 2001;22(6):957–966. doi:10.1016/S0197-4580(01)00306-2.
13. Dong Y, Li X, Cheng J, Hou L, Zhang J, Liu Y. Neuroinflammation as a target for treatment of Parkinson's disease. Neurochem Res. 2020;45(5):1045–1056. doi:10.1007/s11064-020-02995-7.
14. Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. Mass spectrometric detection of early glycation products on human serum albumin. Anal Chem. 2017;79(5):2556–2564. doi:10.1021/ac061919d.
15. Poulsen MW, Hedegaard RV, Andersen JM, De Courten B, Bügel S, Nielsen J, et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol. 2013;60:10–37. doi:10.1016/j.fct.2013.06.052.
16. Nielsen ML, Savitski MM, Zubarev RA, Schmid M. Proteomic and structural analysis of glycated proteins. J Proteom Res. 2015;14(3):1195–1203. doi:10.1021/pr5009713.
17. Ahmed N, Thornalley PJ, Rabbani N. Protein glycation, oxidative stress and ageing. Biochem J. 2020;477(6):1153–1162. doi:10.1042/BCJ20190455.
18. Chen J, Xu H, Li M, Li G. A novel molecular dynamics simulation for the interactions between amyloid-beta peptide and AGEs. J Mol Struct. 2018;1160:356–365. doi:10.1016/j.molstruc.2018.02.034.
19. Thornalley PJ, Rabbani N, Ahmed N. Advances in therapeutic inhibition of advanced glycation endproducts. Biochem Pharmacol. 2021;189:114240. doi:10.1016/j.bcp.2020.114240.
20. Chen J, Liu Q, Zhang R. Inhibition of advanced glycation end-product formation as a strategy for managing neurodegeneration. Front Pharmacol. 2019;10:1072. doi:10.3389/fphar.2019.01072.
21. Yan SD, Schmidt AM. Receptor for advanced glycation end-products (RAGE) as a therapeutic target: Mapping the path forward. Neurotherapeutics. 2016;13(2):223–238. doi:10.1007/s13311-016-0405-2.
22. Zhao L, Smith MA. RAGE and Alzheimer's disease: Targets for therapeutic intervention. Aging Dis. 2018;9(5):958–970. doi:10.14336/AD.2017.1105.
23. Uribarri J, Cai W, Sandu O, Vlassara H. Dietary advanced glycation endproducts and their role in health and disease. Adv Nutr. 2015;6(4):463–471. doi:10.3945/an.115.008433.
24. Liu S, Zhao J, Li X, Wang Y. Dietary polyphenols and their anti-glycation effects: Potential therapeutic roles in neurodegenerative diseases. Food Chem. 2020;323:126791. doi:10.1016/j.foodchem.2020.126791.
25. Bennett RE, Krishnamurthy S. Advances in high-throughput screening for glycation-targeted therapies in neurodegenerative diseases. Curr Neuropharmacol. 2023;21(2):189–202. doi:10.2174/1570159X216662301230928.

